This is also demonstrated from biologicals such as omalizumab (anti-IL-5 in severe asthma); variability in biologic levels has been shown to impact efficacy when also used in other applications of biologicals, e.g., in Inflammatory Bowel Disease [38]: an adapted personalized protocol was needed for more asthma-related benefit [39, 40]. This evidence concerns the gene IL5 and inflammatory bowel disease.